Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

Core Insights - Tarsus Pharmaceuticals will present data on the global prevalence and patient burden of Demodex blepharitis, along with the efficacy of XDEMVY at the ASCRS 2025 Annual Meeting [1][2] Group 1: Demodex Blepharitis - Demodex blepharitis is a common eyelid disease caused by Demodex mites, affecting over two-thirds of blepharitis cases and potentially impacting 25 million Americans [7] - The Titan study indicates that 58% of patients visiting U.S. eye care clinics show signs of Demodex mite infestation, with 45 million annual visits to eye care clinics [7] Group 2: XDEMVY (Lotilaner Ophthalmic Solution) - XDEMVY is a novel prescription eye drop designed to treat Demodex blepharitis by targeting the underlying mite infestation [8] - Clinical trials involving over 800 patients demonstrated that XDEMVY met primary and secondary endpoints with statistical significance and no serious treatment-related adverse events [8][9] - The most common side effect reported was stinging and burning in 10% of patients, while other adverse reactions were less than 2% [9][11] Group 3: Upcoming Presentations - The ASCRS meeting will feature several presentations, including: - A longitudinal evaluation of disease burden and treatment efficacy in patients with Demodex blepharitis [3] - A study assessing specific symptoms of Demodex blepharitis [4] - Research on the treatment of Demodex blepharitis in patients with Meibomian gland dysfunction [5] - An observational study on the prevalence of Demodex blepharitis in Japan [6]